SillaJen, Inc. (KOSDAQ:215600)
South Korea · Delayed Price · Currency is KRW 3,740.00
-50.00 (-1.32%)
At close: Feb 6, 2026
SillaJen Revenue
SillaJen had revenue of 2.76B KRW in the quarter ending September 30, 2025, with 114.16% growth. This brings the company's revenue in the last twelve months to 7.84B, up 537.61% year-over-year. In the year 2024, SillaJen had annual revenue of 3.93B, down -0.33%.
Revenue (ttm)
7.84B
Revenue Growth
+537.61%
P/S Ratio
65.89
Revenue / Employee
137.56M
Employees
57
Market Cap
516.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.93B | -12.90M | -0.33% |
| Dec 31, 2023 | 3.94B | -1.07B | -21.42% |
| Dec 31, 2022 | 5.01B | 4.76B | 1,870.95% |
| Dec 31, 2021 | 254.36M | -1.42B | -84.77% |
| Dec 31, 2020 | 1.67B | -7.40B | -81.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Holdings | 2.40T |
| Bioneer | 320.69B |
| Medy-Tox | 241.80B |
| BINEX | 165.64B |
| JETEMA, | 75.55B |
| Onconic Therapeutics | 46.65B |
| Pharmicell | 23.94B |
| Anterogen.Co.,Ltd. | 7.32B |